Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient

Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient

A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2019-10, Vol.25 (20), p.6015-6017
1. Verfasser: Fathi, Amir T
Format: Artikel
Sprache:eng
Schlagworte:
Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Cytarabine
Hedgehog Proteins
Humans
Leukemia, Myeloid, Acute
Phenylurea Compounds
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timely and valuable for the oncology community. .
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-19-1986